Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities). HCR royalty deal amended: change-of-control payment slashed from up to $750M to $150M (before 2028) or $200M (after 2028).
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- HCR royalty deal amended: change-of-control payment slashed from up to $750M to $150M (before 2028) or $200M (after 2028)
- Post-acquisition royalty obligations can be bought out for $525M (by end 2029) or $750M (by end 2030), less prior royalties paid and CoC payment
- Amendment dramatically lowers upfront CoC cost, making ADCT a more attractive acquisition target by reducing deal friction
- HCR originally provided $300M in funding; amended terms structurally favor a cleaner M&A exit for a potential acquirer
Item 3.02 · Unregistered Sales of Equity Securities
- Warrants issued to HCR for 9,834,776 common shares at $3.8130/share, exercisable through Dec 31, 2030
- Lock-up on warrant transfers and underlying shares until Dec 31, 2027: limits near-term selling pressure but caps HCR's flexibility
- Change-of-control trigger: if all-cash/marketable securities deal, warrants auto-exercise immediately prior to closing; protects HCR in M&A
- Company must file resale registration statement within 30 business days, creating future public float overhang of ~9.8M shares
- Cashless exercise option available, but Swiss law constraints on freely distributable equity may limit share delivery in some scenarios
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.